ClinicalTrials.gov
public full text
Public Domain
Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.
In this proposal, the investigators aim to explore the clinical subtypes and biological markers to personalize the use of antidepressants in MDD. By stratifying the subjects with (versus without) remission and treatment response, the biological markers are expected to have important prediction effects in future clinical practice.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression#875061
- Phenotype Depression Study#843158
- A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment#835266
- Public thresholds for antidepressant effectiveness and adverse drug reaction rates: a cross-sectional study.#375360
- Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence#839148
Record · ID 898787
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive